{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:49:04Z","timestamp":1788608944506,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","award":["106-2320-B-002-032-MY3"],"award-info":[{"award-number":["106-2320-B-002-032-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.mayocp.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T07:02:53Z","timestamp":1561964573000},"page":"1147-1157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study"],"prefix":"10.1016","volume":"94","author":[{"given":"Ching-Yen","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-3205","authenticated-orcid":false,"given":"Li-Jiuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Chou","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-7481","authenticated-orcid":false,"given":"Fang-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mayocp.2019.03.001_bib1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","article-title":"The global burden of gout: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Smith","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mayocp.2019.03.001_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.mayocp.2019.03.001_bib3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.001_bib4","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.001_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.mayocp.2019.03.001_bib6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.001_bib7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.001_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.001_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.001_bib10","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.001_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.semarthrit.2012.11.002","article-title":"Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database","volume":"42","author":"Gandhi","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"13","key":"10.1016\/j.mayocp.2019.03.001_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.001_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.mayocp.2019.03.001_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.001_bib16","first-page":"500","article-title":"Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan","volume":"24","author":"Cheng","year":"2014","journal-title":"J\u00a0Epidemiol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.001_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pds.2087","article-title":"Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan","volume":"20","author":"Cheng","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.001_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1753-6405.2011.00739.x","article-title":"Accuracy of national mortality codes in identifying adjudicated cardiovascular deaths","volume":"35","author":"Harriss","year":"2011","journal-title":"Aust N Z J Public Health"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.001_bib19","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3899\/jrheum.141542","article-title":"Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study","volume":"42","author":"Chen","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.001_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.001_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology","volume":"117","author":"Cushman","year":"2004","journal-title":"Am J Med"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2019.03.001_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pds.2313","article-title":"A\u00a0systematic review of validated methods for identifying heart failure using administrative data","volume":"21","author":"Saczynski","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.001_bib23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/1756-185X.13266","article-title":"Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan","volume":"21","author":"Yu","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2019.03.001_bib24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A\u00a0benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.001_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.001_bib26","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the Standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.mayocp.2019.03.001_bib28","unstructured":"FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat). US Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat. Published February 21, 2019. Accessed February 25, 2019."},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.001_bib29","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.ajkd.2014.04.024","article-title":"Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002","volume":"64","author":"Odden","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.001_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/RHU.0000000000000496","article-title":"Evaluation of the relationship between serum uric acid levels and cardiovascular events in patients with gout: a retrospective analysis using electronic medical record data","volume":"23","author":"Essex","year":"2017","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.001_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3899\/jrheum.160792","article-title":"Sex-specific relationship of serum uric acid with all-cause mortality in adults with normal kidney function: an observational study","volume":"44","author":"Kang","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.001_bib32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0891-5849(93)90143-I","article-title":"Towards the physiological function of uric acid","volume":"14","author":"Becker","year":"1993","journal-title":"Free Radic Biol Med"},{"issue":"3-4","key":"10.1016\/j.mayocp.2019.03.001_bib33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000443769","article-title":"Hyperuricemia, cardiovascular disease, and hypertension","volume":"3","author":"Kuwabara","year":"2016","journal-title":"Pulse (Basel)"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.001_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.001_bib35","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619302526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619302526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T02:47:10Z","timestamp":1569034030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619302526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0025619619302526"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}